

26 February 2015

iQnovate Limited receives approval to be upgraded to the OTCQB Marketplace

SYDNEY, Australia, February 24, 2015 – iQnovate Limited (NSX:IQN, OTC Pink: IQNDY), a life science organization providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry, announced today that it has received approval to be upgraded to the OTCQB Marketplace.

The OTCQB is a venture stage marketplace for U.S. and international Companies.

The OTCQB represents a great market for iQnovate Limited that will allow **iQN to strengthen its presence in the U.S. investment landscape.**

The upgrade to OTCQB also has significant benefits for iQN shareholders and potential investors with the subsequent move to Real-Time Level 2 Quotation of iQN's securities.

Key Benefits

- **Improves Price Discovery** – Investors can trade with confidence, knowing they are getting the best price since transparent pricing is widely available
- **Build Visibility** – Investors can closely track market activity and have better insight into available liquidity when they are able to see each broker-dealer quote price and size

“iQN continues to create a solid multinational shareholder infrastructure as part of executing the iQN global growth strategy through M&A” commented George Syrmalis, Chief Executive Officer of iQNovate Limited. **“The primary benefit of upgrading to the OTCQB is to expand the investor base and broaden access for brokers and dealer groups in the North American market to enable them to trade iQN securities, further improving the liquidity of iQN”.**

Kelvin Boateng - Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Limited

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.